Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 2
2006 1
2007 2
2010 4
2011 3
2012 4
2013 15
2014 10
2015 4
2016 4
2017 3
2018 2
2019 2
2020 3
2021 5
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A. Cremolini C, et al. Among authors: carlomagno c. Lancet Oncol. 2015 Oct;16(13):1306-15. doi: 10.1016/S1470-2045(15)00122-9. Epub 2015 Aug 31. Lancet Oncol. 2015. PMID: 26338525 Clinical Trial.
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A. Loupakis F, et al. Among authors: carlomagno c. N Engl J Med. 2014 Oct 23;371(17):1609-18. doi: 10.1056/NEJMoa1403108. N Engl J Med. 2014. PMID: 25337750 Free article. Clinical Trial.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Among authors: carlomagno c. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Free article. Clinical Trial.
Ipilimumab in the treatment of metastatic melanoma: management of adverse events.
Della Vittoria Scarpati G, Fusciello C, Perri F, Sabbatino F, Ferrone S, Carlomagno C, Pepe S. Della Vittoria Scarpati G, et al. Among authors: carlomagno c. Onco Targets Ther. 2014 Feb 19;7:203-9. doi: 10.2147/OTT.S57335. eCollection 2014. Onco Targets Ther. 2014. PMID: 24570590 Free PMC article. Review.
New approach to implement cancer patient care: The valutazione percorso rete oncologica campana (ValPeROC)-experience from an Italian oncology network.
Crispo A, Rivieccio G, Cataldo L, Coluccia S, Luongo A, Coppola E, Grimaldi M, Montagnese C, Nocerino F, D'Errico D, Celentano E, Saviano R, Bastone A, Baglio G, De Angelis C, Ciardiello F, Avallone A, Cassata A, Costanzo R, Morabito A, Maione P, Gridelli C, Cigolari S, Borrelli A, De Placido S, Schiavone F, Bianchi AAM, Pignata S; ValPeROC Group. Crispo A, et al. Eur J Cancer Care (Engl). 2022 Nov;31(6):e13736. doi: 10.1111/ecc.13736. Epub 2022 Oct 25. Eur J Cancer Care (Engl). 2022. PMID: 37039607
Non-Operative Management Versus Total Mesorectal Excision for Locally Advanced Rectal Cancer with Clinical Complete Response After Neoadjuvant Chemoradiotherapy: a GRADE Approach by the Rectal Cancer Guidelines Writing Group of the Italian Association of Medical Oncology (AIOM).
Capelli G, De Simone I, Spolverato G, Cinquini M, Moschetti I, Lonardi S, Masi G, Carlomagno C, Corsi D, Luppi G, Gambacorta MA, Valvo F, Cannizzaro R, Grillo F, Barbaro B, Restivo A, Messina M, Pastorino A, Aschele C, Pucciarelli S. Capelli G, et al. Among authors: carlomagno c. J Gastrointest Surg. 2020 Sep;24(9):2150-2159. doi: 10.1007/s11605-020-04635-1. Epub 2020 May 11. J Gastrointest Surg. 2020. PMID: 32394125 Free article. Review.
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients.
Cuomo A, Mercurio V, Varricchi G, Galdiero MR, Rossi FW, Carannante A, Arpino G, Formisano L, Bianco R, Carlomagno C, De Angelis C, Giuliano M, Matano E, Picardi M, Salvatore D, De Vita F, Martinelli E, Della Corte CM, Morgillo F, Orditura M, Napolitano S, Troiani T, Tocchetti CG. Cuomo A, et al. Among authors: carlomagno c. ESC Heart Fail. 2022 Jun;9(3):1666-1676. doi: 10.1002/ehf2.13879. Epub 2022 Apr 1. ESC Heart Fail. 2022. PMID: 35362255 Free PMC article.
64 results